CML biology for the clinician in 2011: Six impossible things to believe before breakfast on the way to cure

Current Oncology

Volumn 18, Issue 4, 2011, Pages

  Leber, B ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Apoptosis; Leukemia; Stem cells; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CHLOROQUINE; DASATINIB; IMATINIB; INTERFERON; NAVITOCLAX; OBATOCLAX; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SMOOTHENED PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; ENZYME ACTIVITY; FUSION GENE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROMYELOCYTIC LEUKEMIA;

EID: 80051528837     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i4.652     Document Type: Article

References (28)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
2. Rudkin CT, Hungerford DA, Nowell PC. DNA contents of chromosome Ph1 and chromosome 21 in chronic granulocytic leukemia. Science 1964;144:1229-31.
3. Teyssier JR, Bartram CR, Deville J, Potron G, Pigeon F. c-abl Oncogene and chromosome 22 "bcr" juxtaposition in chronic myelogenous leukemia. N Engl J Med 1985;312:1393-4.
4. Shah NP, Kasap C, Weier C, et al. Transient potent Bcr-Abl inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008;14:485-93.
5. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 2008;30:11-25.
6. Leber B, Lin J, Andrews DW. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 2007;12:897-911.
7. Belloc F, Moreau-Gaudry F, Uhalde M, et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.Cancer Biol Ther 2007;6:912-19.
8. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.Proc Natl Acad Sci U S A 2006;103:14907-12.
9. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
10. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance apoptosis. Proc Natl Acad Sci U S A 2007;104:19512-17.
11. Belloc F, Airiau K, Jeanneteau M, Mahon FX. ABT-737 cooperates in a strong synergism with tyrosine kinase inhibitors to induce apoptosis of chronic myeloid leukemia cells [abstract 3246]. Blood 2009;114:22.
12. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004;351:657-67.
13. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A 2009;106:3925-9.
14. Koptyra M, Falinski R, Nowicki MO, et al. Bcr/Abl kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319-27.
15. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70.
16. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006;12:1181-4.
17. Mahon FX, Réa D, Guilhot J, et al. on behalf of the Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.Lancet Oncol 2010;11:1029-35.
18. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
19. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006;12:1175-80.
20. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.Nat Med 2006;12:1167-74.
21. Essers MA, Offner S, Blanco-Bose WE, et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-8.
22. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238-49.
23. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-9.
24. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072-8.
25. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109-23.
26. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the ALOX5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783-92.
27. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potentlyinduces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.Blood 2008;111:2843-53.
28. Pellicano F, Copland M, Jorgensen HG, Mountford J, Leber B,Holyoake TL. BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ.Blood 2009;114:4186-96.